IP Group sold a $5m stake to biopharmaceutical company Celltrion as part of a series A round for oncology therapy developer Iksuda.

UK-based antibody drug conjugate (ADC) developer Iksuda Therapeutics has closed a $47m series A round that included a $5m stake sale by commercialisation firm IP Group to an incoming shareholder, biopharmaceutical firm Celltrion.

Celltrion co-led the round with Premier Partners, Mirae Asset and Mirae Asset’s subsidiaries. IP Group owns a 19.4% stake in Iksuda following the deal.

Founded in 2007 as Glythera, Iksuda is working on ADCs targeting tumours that have limited treatment options and high relapse rates. Its lead…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn